Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07300085 · ClinicalTrials.gov registry record · Phase 1

A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine

A Phase 1 study of Healthy Participants, sponsored by Cidara Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
2
Study locations

NCT07300085 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Cidara Therapeutics. The registered enrollment target is 100 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07300085, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Cidara Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical study is to investigate how safe and effective it is to receive both the Fluzone® High-Dose (HD) influenza vaccine and CD388, a long-acting antiviral medicine, at the same time. Some participants will receive the vaccine and CD388, while others will receive the vaccine and a placebo. The study aims to determine whether taking CD388 together with the flu vaccine affects the body's ability to build protection-called an immune response-against the flu, as compared to getting the vaccine with a placebo. The hypothesis is that giving both at the same time does not weaken the immune response to the vaccine. The study will measure the amount of antibodies (proteins produced by the immune system to fight flu viruses) generated by participants in both groups to check that CD388 does not interfere with how well the vaccine works. Participants will also be closely watched for any side effects or reactions to check that CD388 is safe to take alongside the vaccine. Expanded access to the study treatments (flu vaccine and CD388) will not be provided to participants after the study ends.

Conditions Studied

Healthy Participants

Interventions

  • COMBINATION_PRODUCT Placebo
  • BIOLOGICAL Fluzone HD influenza vaccine
  • COMBINATION_PRODUCT CD388 Injection

Study Locations (2)

California

  • California Clinical Trials Medical Group (CCTMG) managed by Parexel - Glendale

Maryland

  • Parexel International - EPCU Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-11-08
Est. Completion 2026-05
Phase Phase 1

Sponsor

Cidara Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07300085

The ClinicalTrials.gov registry entry for NCT07300085 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% higher). The listed sponsor is Cidara Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07300085 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.

Frequently Asked Questions

What is clinical trial NCT07300085 about?

NCT07300085 is a clinical study titled "A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine". The goal of this clinical study is to investigate how safe and effective it is to receive both the Fluzone® High-Dose (HD) influenza vaccine and CD388, a long-acting antiviral medicine, at the same time. Some participants will receive the vaccine and CD388, while others will receive the vaccine and ...

What is the current status of trial NCT07300085?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-11-08. Estimated completion is 2026-05.

What conditions does trial NCT07300085 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT07300085?

The interventions under investigation include: Placebo (COMBINATION_PRODUCT), Fluzone HD influenza vaccine (BIOLOGICAL), CD388 Injection (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT07300085?

This trial is sponsored by Cidara Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07300085 being conducted?

This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy Participants

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.